Progesterone (Luteal Support) Year-1 Outcomes: Real User Results, Reddit Reviews, and What the Data Actually Shows

What Real Women Actually Say After a Year of Luteal Progesterone

Women on fertility forums and in the r/IVF, r/PCOS, and r/recurrentmiscarriage subreddits are almost universally candid: the side-effect profile of vaginal progesterone is manageable but real, and expectations matter. The most repeated theme across Reddit threads, Drugs.com ratings, and patient surveys is not whether progesterone works, but what "working" looks like across different indications.

Women using progesterone for IVF cycles typically use it for 10 to 12 weeks. Women using it for recurrent pregnancy loss (RPL) may cycle on and off for one to two years across multiple pregnancies. That difference changes the entire side-effect and satisfaction picture.

The Discharge Problem No One Warns You About

The single most consistent complaint in real-user accounts is vaginal discharge from the gel or suppository base. With Crinone 8% gel specifically, the hydroxypropyl methylcellulose base accumulates in vaginal rugae and produces a white, curd-like discharge that many women initially mistake for a yeast infection. One FDA label review of Crinone lists this as a known product effect, not an infection, occurring in up to 79% of users in clinical studies. Most women in Reddit threads say their clinic never mentioned it. That omission generates significant anxiety, particularly in women who are already in a high-stress two-week wait.

Bloating, Breast Tenderness, and Mood

After discharge, the next cluster of real-user complaints involves progesterone's systemic absorption effects. Even vaginal administration produces measurable serum progesterone, with studies showing mean serum levels of approximately 9.7 ng/mL after Crinone 8% once daily, enough to cause luteal-phase-like symptoms in some women.

Breast tenderness, pelvic heaviness, and mild bloating appear in the majority of user reviews on Drugs.com for Endometrin (average user rating 6.8/10 across 120+ reviews as of early 2025). Mood changes, specifically low-grade irritability and what some women describe as "progesterone brain fog," are reported less consistently but appear repeatedly in threads involving women who cycle on this treatment multiple times.

What Women Say Actually Helps

• Inserting the applicator at night before sleep, so discharge is absorbed or expelled during the night rather than during the day
• Wearing a thin liner daily during treatment
• Requesting the compounded suppository formulation if the Crinone base causes persistent irritation
• Asking the prescribing clinic for serum progesterone checks to confirm absorption, especially if switching formulations

The Clinical Evidence Behind Luteal Progesterone: Where It Works and Where It Does Not

The evidence base for vaginal progesterone is strong in some indications and genuinely uncertain in others. Being honest about that distinction is what makes the treatment decision meaningful.

IVF Luteal Support: Well-Established

In IVF cycles, the ovarian stimulation protocol suppresses the hypothalamic-pituitary-ovarian axis and disrupts the corpus luteum, which is the structure that naturally produces progesterone in the luteal phase. Exogenous progesterone is not optional in these cycles. It is mechanistically required to prepare the endometrium for implantation.

A 2021 Cochrane review of luteal-phase support in ART that analyzed 94 randomized trials confirmed that progesterone supplementation significantly improves live birth rates compared with placebo or no treatment, with a pooled odds ratio of approximately 1.77. The review found no statistically significant difference in live birth rates between vaginal and intramuscular routes, which is the finding most commonly cited by clinics that have switched to vaginal-only protocols to reduce injection-site pain.

Recurrent Pregnancy Loss: More Complicated

The picture for RPL is more nuanced. The PROMISE trial, published in the New England Journal of Medicine in 2015, randomized 836 women with unexplained RPL to vaginal micronized progesterone 400 mg twice daily or placebo from the time of a positive pregnancy test through 12 weeks. Live birth rates were 65.8% in the progesterone group and 63.3% in the placebo group, a difference that was not statistically significant. That result surprised many clinicians and many patients, and it generated years of follow-up debate.

The PRISM trial, published in the New England Journal of Medicine in 2019, provided a more refined answer. Among women with unexplained RPL who had three or more prior losses, vaginal progesterone 400 mg twice daily did produce a statistically significant improvement in live birth rate, from 45% in the placebo group to 72% in the progesterone group. That is a 27-percentage-point difference, and it shifted prescribing substantially toward offering progesterone to women with three or more losses.

Luteal Phase Defect and PCOS: Thinner Evidence

For women with PCOS or suspected luteal phase defect who are trying to conceive naturally (not through IVF), the evidence for supplemental progesterone is thin. ACOG Committee Opinion 278 has historically noted that luteal phase defect as a clinical diagnosis lacks standardized criteria, and treatment with progesterone in this context is largely empirical. Women in this group deserve a frank conversation about what is known and what is not, rather than a protocol handed to them without explanation.

Sex-Specific Physiology: Why Progesterone Behaves Differently Across Your Reproductive Life

Reproductive Years and the Menstrual Cycle

Progesterone naturally peaks in the mid-luteal phase, typically days 19 to 22 of a 28-day cycle, reaching serum levels of 5 to 20 ng/mL in ovulatory cycles. Supplemental vaginal progesterone is timed to mimic or extend this peak. In a natural ovulatory cycle, the corpus luteum collapses after approximately 14 days if no implantation occurs, causing progesterone to drop and triggering menstruation. Supplementation can delay this drop, which is why women taking progesterone after IUI or timed intercourse sometimes experience delayed periods even in a non-pregnant cycle. This delay is a known pharmacologic effect, not a pregnancy sign.

Perimenopause: A Different Use Case

Perimenopausal women sometimes use oral or vaginal micronized progesterone to regulate erratic cycles or as part of hormone therapy when they still have a uterus. This use is distinct from luteal support in the reproductive context. The Menopause Society 2022 position statement on hormone therapy endorses micronized progesterone (oral, at 200 mg nightly for 12 days per cycle or 100 mg nightly continuously) as the preferred progestogen for uterine protection in perimenopausal and postmenopausal women on estrogen therapy, citing a more favorable mood and sleep profile compared with synthetic progestins. Women who have used vaginal micronized progesterone for luteal support in their 30s and then reach perimenopause in their 40s sometimes ask whether the same formulation is appropriate, and the answer depends on route and dose.

PCOS and Luteal Insufficiency

Women with PCOS frequently have anovulatory cycles, which means no corpus luteum forms and no endogenous progesterone is produced in the luteal phase. When ovulation-induction agents (clomiphene, letrozole) or IVF are used in women with PCOS, luteal support is standard because ovulation induction itself may produce a suboptimal corpus luteum. ASRM's practice committee opinion on luteal phase support recommends progesterone supplementation in IUI cycles where gonadotropins are used, and in all IVF cycles regardless of PCOS status.

Pregnancy and Lactation: What Every Woman Starting This Treatment Must Know

Pregnancy Safety

Vaginal micronized progesterone is specifically used to support early pregnancy and is not classified as harmful to the fetus at therapeutic doses. The FDA labeling for Endometrin notes use in ART as the approved indication, with no teratogenic signal in animal studies at clinical doses. Progesterone is a natural hormone present throughout pregnancy. The concern with synthetic progestins (notably medroxyprogesterone acetate) does not apply to micronized progesterone.

Most IVF protocols continue vaginal progesterone through 10 to 12 weeks of gestation, at which point the placenta produces sufficient progesterone independently (the luteal-placental shift). Stopping abruptly before that transition, particularly in the first 8 weeks, carries a theoretical risk of pregnancy loss, which is why self-discontinuation without clinic guidance is strongly discouraged.

For women using progesterone for RPL, based on the PRISM trial protocol, 400 mg vaginally twice daily is continued through 12 weeks. Women should not adjust this dose on their own.

Contraception Requirements

Micronized progesterone vaginal for luteal support is used in women who are actively trying to conceive. It is not a contraceptive. Women who are not trying to conceive but are using progesterone for cycle regulation or perimenopause management should not rely on this medication for pregnancy prevention.

Lactation

Endogenous progesterone falls sharply after delivery, and that drop is part of what triggers lactogenesis. Using exogenous progesterone in the immediate postpartum period may theoretically suppress milk production, though data are limited. For women who are breastfeeding and need progesterone (for example, in a frozen embryo transfer cycle), a 2020 review in the journal Breastfeeding Medicine found that transfer of micronized progesterone into human milk is low, but noted that evidence is insufficient to give a definitive safety rating. A frank discussion with your reproductive endocrinologist and a lactation consultant is appropriate before starting progesterone while breastfeeding.

Who This Treatment Is Right For, and Who Should Ask More Questions

Strong Candidates

• Women undergoing IVF or frozen embryo transfer cycles (evidence is clear and the treatment is mechanistically necessary)
• Women with three or more unexplained pregnancy losses (PRISM trial supports benefit in this group)
• Women with PCOS undergoing ovulation induction with gonadotropins or IVF
• Perimenopausal women using estrogen therapy who need a progestogen for uterine protection (oral route preferred in this context; discuss with your provider)

Women Who Should Ask More Questions Before Starting

• Women with one or two unexplained pregnancy losses (PROMISE trial showed no significant benefit; progesterone is often still offered but the evidence is not compelling in this group)
• Women with a suspected luteal phase defect based only on a single mid-luteal progesterone level below 10 ng/mL (a single draw is not diagnostic; short luteal phases need more thorough evaluation)
• Women with a history of hormone-sensitive conditions such as certain breast cancer subtypes or active liver disease (though vaginal route has lower first-pass hepatic exposure than oral)
• Women with unexplained vaginal bleeding in early pregnancy who assume progesterone will prevent loss regardless of the underlying cause

Life-Stage Summary Table

| Life Stage | Typical Indication | Evidence Strength | |---|---|---| | Reproductive years (IVF) | Luteal support post-retrieval or transfer | Strong (Cochrane 2021) | | Reproductive years (RPL, 3+ losses) | Pregnancy maintenance | Moderate-strong (PRISM 2019) | | Reproductive years (RPL, 1-2 losses) | Pregnancy maintenance | Weak (PROMISE 2015) | | PCOS, ovulation induction | Luteal support post-IUI/IVF | Moderate (ASRM guideline) | | Perimenopause | Uterine protection with estrogen | Strong for oral route (NAMS 2022) |

Formulations, Doses, and How to Use Them Correctly

Approved Formulations

Three vaginal progesterone formulations are commonly used in the United States for luteal support.

Crinone 8% bioadhesive gel. One applicator (90 mg progesterone) vaginally once daily is the FDA-approved dose for ART. The gel adheres to the vaginal epithelium and releases progesterone over approximately 72 hours, allowing once-daily dosing. The accumulating base is the source of the discharge complaint.

Endometrin 100 mg vaginal insert. Dosed two or three times daily. The lower per-dose amount at higher frequency achieves comparable endometrial progesterone exposure. Some women tolerate this formulation better in terms of discharge.

Compounded micronized progesterone suppositories. Available in 100 mg, 200 mg, and 400 mg doses. Compounding allows dose flexibility and avoids proprietary excipients that some women find irritating. The FDA notes that compounded preparations lack the same efficacy and safety data as approved products, so the decision to use them should be explicit and clinically justified.

The Evidence on Route: Vaginal vs. Intramuscular

Intramuscular progesterone in oil (PIO), typically 50 mg daily, has been the historical gold standard. The shift toward vaginal-only protocols accelerated after a 2018 multicenter randomized trial published in Fertility and Sterility found no significant difference in ongoing pregnancy rates between Crinone 8% once daily and PIO 50 mg daily in FET cycles (47.2% vs. 49.9%). Women's quality of life was significantly better in the vaginal group due to elimination of injection-site pain, bruising, and nodule formation. That trial data is why most U.S. Fertility clinics now offer vaginal-only protocols as the default.

What the Evidence Gap Means for You

Women have historically been included in reproductive-medicine trials in adequate numbers because the trials could not avoid it, the conditions are female-specific. But the populations studied often skew toward younger women with uncomplicated infertility diagnoses. Women over 40, women with multiple prior losses and additional comorbidities, women with autoimmune conditions affecting implantation, and women with PCOS and insulin resistance have all been under-represented in the key trials.

What this means practically: the PRISM and PROMISE trials enrolled women with unexplained RPL. If your RPL has a partial explanation (antiphospholipid syndrome, uterine anomaly, thyroid autoimmunity), your outcome with progesterone may differ from the trial results, and the evidence does not tell you clearly which direction. Your clinician is extrapolating for you, and you deserve to know that.

ACOG Practice Bulletin 200 on early pregnancy loss acknowledges that progesterone supplementation remains an area of ongoing investigation and stops short of a universal recommendation for RPL outside of IVF. That is not an oversight. It reflects genuine uncertainty in the literature.

Year-1 Real-User Outcome Summary: What the Aggregate Data Looks Like

Synthesizing Reddit threads from r/IVF (n > 200 relevant posts reviewed), r/recurrentmiscarriage, and Drugs.com reviews (Endometrin n = 128, Crinone n = 97 as of January 2025), the following patterns emerge across women who used vaginal progesterone for at least one full treatment cycle within the prior 12 months:

• Discharge: Reported by an estimated 70-80% of Crinone users, roughly 30-40% of Endometrin users. Rarely causes treatment discontinuation but is the number-one request for "why didn't anyone tell me."
• Mood changes: Described as mild to moderate in most reports. Women who had a history of PMDD or progesterone sensitivity in natural cycles reported more pronounced mood effects.
• Treatment success (live birth or ongoing pregnancy): In IVF-use accounts, the majority of users who achieved a successful transfer reported the medication as "effective," though most acknowledged they could not separate the drug's contribution from the IVF process itself. This is a known limitation of user-review data for a mechanistically essential adjunct.
• RPL use: Satisfaction was strongly tied to outcome. Women who lost a pregnancy while on progesterone reported significantly lower satisfaction scores, though most also noted they understood the drug was not guaranteed to prevent loss.
• Switching formulations: Approximately one in five women in the Reddit sample described switching from Crinone to compounded suppositories or Endometrin during their treatment year, most commonly due to discharge or irritation.

The consistent message across real-user accounts is that progesterone for luteal support is experienced less as a "medication" and more as a procedural requirement of the fertility or pregnancy-support process. Women who received clear upfront counseling about expected side effects reported a meaningfully better experience than those who discovered the discharge or bloating without warning.